Testing a new drug combination for relapsed marginal zone lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares a combination of mosunetuzumab and lenalidomide against standard treatments for people with marginal zone lymphoma that has come back or stopped responding to previous therapy. It aims to find out if the new combination works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with marginal zone lymphoma (a slow-growing type of lymphoma).
- You have received at least 1 but no more than 3 previous treatments for lymphoma, including a CD20-targeting drug (like rituximab).
- Your disease is causing symptoms and needs more treatment, but local treatments like surgery or radiation are not an option.
- You are 18 years or older and able to provide consent for participation.
- Your heart, kidney, liver, and blood cell counts are within acceptable ranges for this study.
- You are not pregnant, and you agree to use effective birth control during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether mosunetuzumab, added to lenalidomide, can treat people who have not yet received lymphoma medicines. It’s for follicular lymphoma or marginal zone lymphoma and may help shrink tumors and improve control of the disease.
This trial studies whether obinutuzumab combined with lenalidomide can control marginal zone lymphoma that has come back or not responded to prior treatment. If you qualify, you may receive these medicines together to help shrink tumors and improve symptoms.
This trial tests a combination of two medicines—pirtobrutinib (a targeted pill) and rituximab (an infusion)—for people with marginal zone lymphoma who have not had any prior systemic treatment. The goal is to see if this combination works better than standard treatments.
This study tests three different treatment combinations using new drugs (mosunetuzumab alone, or combined with zanubrutinib or polatuzumab vedotin) for marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to find which combination works best and is safest.
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of two drugs, Mosunetuzumab and Tislelizumab, for people with relapsed or refractory follicular lymphoma. The goal is to see if this combination can help when at least two prior treatments have stopped working.
Hear when a new Marginal Zone Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.